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tively. Feasibility was tested by computing the number of missing
answers; content validity was tested by computing the frequency
of questions considered as “not relevant” by the patients; relia-
bility was tested in terms of internal consistency and test-retest
reproducibility. RESULTS: No missing answers were present in
both the ﬁrst and the second interview. The frequency of “not
relevant” questions was 5.4% on ﬁrst and 7.7% on second inter-
view. The Cronbach’s alpha coefﬁcient for internal consistency
was 0.787 on the ﬁrst and 0.828 on the second interview.
Regarding reproducibility, the intraclass correlation coefﬁcients
for the total score was 0.983 (p < 0.0001), and the method by
Bland & Altman excluded the presence of biases for this score.
The weighted kappa coefﬁcient of agreement calculated for each
question ranged from 0.644 (“social & leisure”) to 0.984
(“sport”). CONCLUSION: The Italian version of the DLQI
questionnaire is feasible, valid and reliable. This instrument can
be used to evaluate Health Related Quality of Life in adult
people affected by skin conditions and can be used to assist deci-
sions on treatment and on health care resource allocation.
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OBJECTIVES: The aim of this open label, multicentric study was
to evaluate the corticosteroid-sparing effect of an emollient milk
containing Oat Rhealba® extracts on quality of life of family in
a group of infants aged less than 1-year old with Atopic Der-
matitis (AD). METHODS: Children with mild to moderate AD
(SCORAD index ≥20 and £70) were randomised in two paral-
lel groups: a group with the emollient milk applied twice daily,
and a group receiving no emollient. The use of topical corticoids
(class II & III non-ﬂuorinated desonide corticoids) was allowed
in the event of inﬂammatory ﬂare-ups in both groups. The
primary end point was measurement of the total amount of
topical steroids used (grammes) at six weeks. The secondary end
points were, clinical rating changes (SCORAD index), and
Quality of Life (QoL) using DFI scale. The DFI scale (Dermati-
tis Family Impact questionnaire) was completed by the parents
and aimed at measuring the impact of dermatosis on the quality
of life of children affected and their family. RESULTS: DFI total
score and all its dimensions were comparable upon inclusion
between treated and non treated groups (total score: 5.30 (5.23)
versus 6.42 (5.32) respectively). Improvement was noted for
both groups. A signiﬁcant improvement was only noted in the
treated group for the items about sleep (In the past seven days,
has the child’s eczema had any effect on the sleep of other family
members?) and about consequences (In the past seven days, has
your participation in the child’s treatment had any consequence
on your life?). CONCLUSIONS: After six weeks of treatment,
we noted in the parents of the treated group a signiﬁcant
improvement in sleep due to treatment impact and a reduced
treatment impact on daily life.
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OBJECTIVES: To assess among the French adult population, the
impact of sensitive skin on quality of life using two validated
questionnaires, the SF-12 and HAD-Depression scale.
METHODS: In July 2004 a sample of 1001 individuals selected
among a national representative sample of the French adult pop-
ulation were interviewed by phone according to the quota
method (gender, age, profession of head of family, town category
and region) by ISPOS. Questions on how they perceived their
skin sensitivity and possible aggravating factors were asked.
Quality of life was then assessed through the SF-12 and the HAD
depressive symptomatology scale. RESULTS: When asked «Do
you have sensitive skin?”, 20.7% answered “very sensitive”,
38.2% “sensitive”, 27.5 % “hardly sensitive”, 13.2% “not sen-
sitive” and 0.5% “gave no answer”. Physical and mental quality
of life was assessed through the SF-12. Regarding the physical
dimension, mean PCS-12 score was 49.2 (SD = 8.6) in the group
“very sensitive or sensitive” against 50.6 (SD = 8) in the group
“hardly or not sensitive” (p = 0.0134). Regarding the mental
dimension, mean MCS-12 score was 45.9 (SD = 9.9) in the group
“very sensitive or sensitive” against 48.1 (SD = 9.7) in the group
“hardly or not sensitive» (p = 0.0004). Evaluation of depressive
symptomatology using the HAD scale showed that there was no
signiﬁcant link between depressive symptomatology and skin
sensitivity: in the group “very sensitive or sensitive”, 4.3% of
subjects presented a certain depressive symptomatology against
4.8% in the group “hardly or not sensitive”. CONCLUSION:
According to the SF-12 scale, the higher the sensitivity, the more
affected is quality of life. Nevertheless, the HAD-Depression
scale, which measures depressive symptomatology, did not bring
to the fore any relation with skin sensitivity.
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OBJECTIVES: To identify the most important determinants of
quality of life (QoL) for adults with Atopic Dermatitis (AD) and
for the parents of children with AD. METHODS: The QoLIAD
is a 25-item needs-based instrument assessing QoL in adults with
AD. The PIQoL-AD is a 28-item instrument assessing the QoL
of parents who have children with AD. These questionnaires
have a simple “Yes”/“No” response option and scores range
from zero to 25/28. Data collected in a six-month, multinational,
open-label study were analysed using Stepwise Multiple Regres-
sion. Demographic, symptom and disease-related variables were
included in the analyses. RESULTS: A total of 319 AD patients
completed the QoLIAD (mean 37.8 years) and 182 parents of
children with AD completed the PIQoL-AD (mean age of child
= 7.4). Regression analyses for the QoLIAD identiﬁed ﬁve vari-
ables; how unhappy/depressed ﬂare-ups make them feel, perfor-
mance at work, number of nights woken during ﬂare-up,
percentage of body affected and age. These ﬁve variables
accounted for 27.2% of the variance in patients’ reported quality
of life (p < 0.0001). For the PIQoL-AD 32.9% of the variance
(p < 0.0001) was accounted for by seven variables; number of
nights woken during ﬂare-up, number of days child misses
school, performance at work, age of child, how unhappy/
depressed their child’s ﬂare-ups make them feel, number of 
ﬂare-ups per year and total time spent with a ﬂare-up each year.
Speciﬁc symptoms such as swelling, itch and redness did not con-
tribute signiﬁcantly to either model. CONCLUSION: These
results reveal that the QoL of adults with AD and the parents of
children who have AD are inﬂuenced by a number of similar
factors. A focus on the symptoms of AD would omit important
inﬂuences on QoL.
